Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States.

Shujing ZhangArielle G BensimonRuifeng XuRuixuan JiangAlexandra GreatsingerAdina ZhangMizuho Fukunaga-KalabisClemens Krepler

Published in: Advances in therapy (2023)

As an adjuvant treatment of stage IIB or IIC melanoma, pembrolizumab was estimated to reduce recurrence, extend patients' life and QALYs, and be cost-effective versus observation at a US willingness-to-pay threshold.

Keyphrases

end stage renal disease
early stage
chronic kidney disease

newly diagnosed
ejection fraction
lymph node

peritoneal dialysis
combination therapy
free survival

patient reported outcomes
epidermal growth factor receptor
replacement therapy